08 December 2023>: Clinical Research
Efficacy Analysis of Neoadjuvant versus Adjuvant Cisplatin-Paclitaxel Regimens for Initial Treatment of FIGO Stages IB3 and IIA2 Cervical Cancer
Wei Tao 1DEF* , Weiqi Wang 1CDF , Jingfang Zhai 2BCF , Linlin Guo 1ABFDOI: 10.12659/MSM.940545
Med Sci Monit 2023; 29:e940545
Figure 2 Progression-free survival between the NT and the AT cohorts. Progression-free survival: survival of patients after adjuvant chemotherapy without recurrence or detection of disease. NT cohort: patients received 70–85 mg/m2 cisplatin plus 165–175 mg/m2 paclitaxel at every 21 days before radical hysterectomy and adjuvant chemotherapy and radiotherapy (if required) after radical hysterectomy; AT cohort: patients received adjuvant chemotherapy and radiotherapy (if required) after radical hysterectomy. χ2 test was used for statistical analysis.